Open AccessIn-vitro targeted alpha-particle therapy (TAT) with 213Bi-Cetuximab outperforms X-Ray irradiation independent of HPV status of HNSCC cell lines
Author(s) -
Michael Siegl,
Christof Seidl,
Frank Bruchertseifer,
Alfred Morgenstern,
Ulrich M. Zissler,
Gabriele Multhoff,
Barbara Wollenberg,
Anja Pickhard
Publication year - 2020
Publication title -
laryngo-, rhino-, otologie
Language(s) - English
Resource type - Conference proceedings
eISSN - 1438-8685
pISSN - 0935-8943
DOI - 10.1055/s-0040-1710998
Subject(s) - cetuximab , cancer research , medicine , oncology , radiation therapy , alpha (finance) , cancer , colorectal cancer , surgery , construct validity , patient satisfaction